Dr. Tom Nolin is a tenured Associate Professor in the Department of Pharmacy & Therapeutics, and in the Department of Medicine Renal-Electrolyte Division at the University of Pittsburgh. Dr. Nolin is the Associate Dean for Research and Sponsored Programs, and he is the Director of the University of Pittsburgh Small Molecule Biomarker Core mass spectrometry facility (www.biomarkers.pitt.edu).
Dr. Nolin is an NIH funded investigator whose primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy (RRT) on nonrenal metabolism and transport pathways and corresponding effects on drug exposure (pharmacokinetics) and response (pharmacodynamics). Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of clinical-translational studies. He served as chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during RRT and as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup. Dr. Nolin has published over 170 manuscripts and book chapters and has presented more than 180 scientific abstracts and invited talks. He serves on the editorial board of the Clinical Journal of the American Society of Nephrology, and as an Editor of DiPiro's Pharmacotherapy: A Pathophysiologic Approach textbook. Dr. Nolin is a Fellow of the American College of Clinical Pharmacy, the American College of Clinical Pharmacology, and of the American Society of Nephrology.
The research focus of the Nolin laboratory includes characterizing the impact of kidney disease and renal replacement therapy on drug exposure (clinical pharmacokinetics) and response (pharmacodynamics), evaluating the functional expression of drug metabolizing enzymes and transporters, developing novel quantitative analytical techniques, and assessing the implications of using various kidney function estimating equations on drug eligibility, selection, and dosing. The long-range goal of our research is to identify the mechanisms by which kidney disease contributes to alterations in these drug elimination pathways, to understand the impact of these alterations on drug response and patient outcomes, and ultimately, to use this information in the development of strategies to optimize drug use in patients with kidney disease.
Click on the PubMed icon underneath the photo for a complete list.
